NASDAQ:XTLB

XTL Biopharmaceuticals Q2 2026 Earnings Results & Report

XTL Biopharmaceuticals logo
$1.58 +0.10 (+6.42%)
As of 10:28 AM Eastern
This is a fair market value price provided by Massive. Learn more.

XTL Biopharmaceuticals reported Q2 2026 earnings on November 18, 2026. The company reported EPS of -$0.05.

Earnings Announcement Details

Quarter
Q2 2026
Time
After Market Closes

XTL Biopharmaceuticals EPS Results

Actual EPS
-$0.05
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

XTL Biopharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

XTL Biopharmaceuticals Q2 2026 Earnings FAQ

XTL Biopharmaceuticals (NASDAQ:XTLB) reported earnings of -$0.05 per share for Q2 2026. The report was announced on Wednesday, November 18, 2026.

XTL Biopharmaceuticals Earnings Headlines

Get your evenings back
The Instant Scanner delivers the night's qualifying setups with exact buy prices and defined exits, in minutes. No hours of flipping through charts, no second-guessing patterns. It's built for traders who want the result without the ritual: a short list and your evening back. Black Friday price is $7 versus the regular $247. One payment covers a full year, with no re-bills.tc pixel
XTL Completed the Acquisition of Psyga Bio Ltd.
See More XTL Biopharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like XTL Biopharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XTL Biopharmaceuticals and other key companies, straight to your email.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals (NASDAQ:XTLB) is an Israel-based company listed on Nasdaq that has focused on developing and commercializing biopharmaceutical products. Its business strategy has also included acquiring and developing pharmaceutical and medical-device businesses.

Historically, the company pursued drug candidates for autoimmune diseases. Its research included hCDR1, an investigational peptide studied for systemic lupus erythematosus. These programs reflect its earlier development work and should not necessarily be understood as products currently marketed by the company.

View XTL Biopharmaceuticals Profile